6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-23), Mersana Therapeutics's 6-1 Month Momentum % is 209.21%.
The industry rank for Mersana Therapeutics's 6-1 Month Momentum % or its related term are showing as below:
MRSN's 6-1 Month Momentum % is ranked better than 96.06% of 1522
companies
in the Biotechnology industry
Industry Median: 1.905
vs MRSN: 209.21
Competitive Comparison
For the Biotechnology subindustry, Mersana Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mersana Therapeutics 6-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Mersana Therapeutics's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Mersana Therapeutics 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Mersana Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mersana Therapeutics (Mersana Therapeutics) Business Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRSN has been successfully added to your